UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 38

Sortiert nach

A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma

Annals of oncology, 2017-04, Vol.28 (4), p.804-808

2017

Volltextzugriff (PDF)

errata

Annals of oncology, 2012-03, Vol.23 (3), p.810-812

2012

Volltextzugriff (PDF)

errata

Annals of oncology, 2012-03, Vol.23 (3), p.810-812

2012

Volltextzugriff (PDF)

1887P Adjuvant everolimus (EVE) in patients (pts) with completely resected very high-risk renal cell cancer (RCC) and clear cell histology: Results from the phase III SWOG S0931 (EVEREST) trial

Annals of oncology, 2023-10, Vol.34, p.S1015-S1015

2023

Volltextzugriff (PDF)

LBA67 Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial

Annals of oncology, 2022-09, Vol.33, p.S1432-S1433

2022

Volltextzugriff (PDF)

P0084 Eribulin in patients with advanced urothelial cancer and previously treated with platinum and anti-microtubule chemotherapy: A phase 2 California Cancer Consortium trial

European journal of cancer (1990), 2015-07, Vol.51, p.e17-e17

2015

Volltextzugriff (PDF)

651O Phase II trial of pembrolizumab (P) in combination with sEphB4-HSA (B4) in previously treated metastatic urothelial carcinoma (mUC)

Annals of oncology, 2021-09, Vol.32, p.S678-S678

2021

Volltextzugriff (PDF)

MA13.08 A Phase 1 Trial of Sapanisertib and Telaglenastat (CB-839) in Patients with Advanced NSCLC (NCI 10327): Results from Dose Escalation

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S91-S92

2022

Volltextzugriff (PDF)

664P Final results from phase I trial of cabozantinib/nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) and peripheral immunity in metastatic genitourinary (mGU) tumors

Annals of oncology, 2021-09, Vol.32, p.S690-S690

2021

Volltextzugriff (PDF)

The hazards of randomized phase II trials

Annals of oncology, 2012-01, Vol.23 (1), p.7-9

2012

Volltextzugriff (PDF)

Acquired Resistance to Targeted Therapies Against Oncogene-Driven Non–Small-Cell Lung Cancer: Approach to Subtyping Progressive Disease and Clinical Implications

Clinical lung cancer, 2014-01, Vol.15 (1), p.1-6

2014

Volltextzugriff (PDF)

LBA50 - Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD)

Annals of oncology, 2019-10, Vol.30, p.v884-v885

2019

Volltextzugriff (PDF)

912PD - Results of the phase II TRAXAR study: A randomized phase II trial of axitinib and TRC105 (TRAX) versus axitinib (AX) alone in patients with advanced or metastatic renal cell carcinoma (mRCC)

Annals of oncology, 2019-10, Vol.30, p.v362-v363

2019

Volltextzugriff (PDF)

Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD)

Annals of oncology, 2019-10, Vol.30, p.v884-v885

2019

Volltextzugriff (PDF)

Results of the phase II TRAXAR study: A randomized phase II trial of axitinib and TRC105 (TRAX) versus axitinib (AX) alone in patients with advanced or metastatic renal cell carcinoma (mRCC)

Annals of oncology, 2019-10, Vol.30, p.v362-v363

2019

Volltextzugriff (PDF)

Bone biomarkers and overall survival (OS) in men with castrate resistant prostate cancer (CRPC) and skeletal metastases: Updated results from SWOG 0421, a phase III trial of docetaxel +/- atrasentan

Annals of oncology, 2016-10, Vol.27, p.vi256-vi256

2016

Volltextzugriff (PDF)

397 Phase 2 results of XL184 in a cohort of patients (pts) with advanced non-small cell lung cancer (NSCLC)

European journal of cancer supplements, 2010, Vol.8 (7), p.126-126

2010

Volltextzugriff (PDF)

Bone metabolism biomarkers (BMB) in hormone sensitive prostate cancer (HSPC): Results from SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) +/- orteronel

Annals of oncology, 2018-10, Vol.29, p.viii275-viii276

2018

Volltextzugriff (PDF)

Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model

Oncogene, 2014-09, Vol.33 (36), p.4521-4530

2014

Volltextzugriff (PDF)

Safety and activity of the pan–fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients with advanced urothelial carcinoma

Annals of oncology, 2016-10, Vol.27, p.vi269-vi269

2016

Volltextzugriff (PDF)

In situ study of structural modifications in Ni-Fe/MgAl2O4 catalysts employed for ethanol steam reforming

Fuel (Guildford), 2024-10, Vol.373, p.132336, Article 132336

2024

Volltextzugriff (PDF)

The effect of the UGT1A128 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis

The pharmacogenomics journal, 2014-10, Vol.14 (5), p.424-431

2014

Volltextzugriff (PDF)

Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small Cell Lung Cancer

Clinical lung cancer, 2017-01, Vol.18 (1), p.1-4

2017

Volltextzugriff (PDF)

7163 Phase II study of eribulin (Halichondrin B analogue, E7389) in patients with advanced urothelial cancer (AUC) – California Cancer Consortium led NCI/CTEP-sponsored trial

European journal of cancer supplements, 2009, Vol.7 (2), p.442-442

2009

Volltextzugriff (PDF)

Abstract IA20: Linking tumor genomics to patient outcomes through a large-scale patient-derived xenograft (PDX) platform

Clinical cancer research, 2014-01, Vol.20 (2_Supplement), p.IA20-IA20

2014

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(38)

Publikationsform

Artikel
(38)

Sprache

Englisch
(38)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Science & Technology
(17)
Life Sciences & Biomedicine
(15)
Humans
(12)
Oncology
(11)
Male
(7)
Hematology, Oncology And Palliative Medicine
(5)
Animals
(4)
Chemotherapy
(4)
Disease Progression
(4)
Female
(4)
Prostate Cancer
(4)
Aged
(3)
Antineoplastic Agents - Therapeutic Use
(3)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(3)
Care And Treatment
(3)
Health Aspects
(3)
Immunology
(3)
Lung Neoplasms - Drug Therapy
(3)
Lung Neoplasms - Pathology
(3)
Middle Aged
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma

errata

errata

1887P Adjuvant everolimus (EVE) in patients (pts) with completely resected very high-risk renal cell cancer (RCC) and clear cell histology: Results from the phase III SWOG S0931 (EVEREST) trial

LBA67 Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial

P0084 Eribulin in patients with advanced urothelial cancer and previously treated with platinum and anti-microtubule chemotherapy: A phase 2 California Cancer Consortium trial

651O Phase II trial of pembrolizumab (P) in combination with sEphB4-HSA (B4) in previously treated metastatic urothelial carcinoma (mUC)

MA13.08 A Phase 1 Trial of Sapanisertib and Telaglenastat (CB-839) in Patients with Advanced NSCLC (NCI 10327): Results from Dose Escalation

664P Final results from phase I trial of cabozantinib/nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) and peripheral immunity in metastatic genitourinary (mGU) tumors

The hazards of randomized phase II trials

Acquired Resistance to Targeted Therapies Against Oncogene-Driven Non–Small-Cell Lung Cancer: Approach to Subtyping Progressive Disease and Clinical Implications

LBA50 - Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD)

912PD - Results of the phase II TRAXAR study: A randomized phase II trial of axitinib and TRC105 (TRAX) versus axitinib (AX) alone in patients with advanced or metastatic renal cell carcinoma (mRCC)

Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD)

Results of the phase II TRAXAR study: A randomized phase II trial of axitinib and TRC105 (TRAX) versus axitinib (AX) alone in patients with advanced or metastatic renal cell carcinoma (mRCC)

Bone biomarkers and overall survival (OS) in men with castrate resistant prostate cancer (CRPC) and skeletal metastases: Updated results from SWOG 0421, a phase III trial of docetaxel +/- atrasentan

397 Phase 2 results of XL184 in a cohort of patients (pts) with advanced non-small cell lung cancer (NSCLC)

Bone metabolism biomarkers (BMB) in hormone sensitive prostate cancer (HSPC): Results from SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) +/- orteronel

Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model

Safety and activity of the pan–fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients with advanced urothelial carcinoma

In situ study of structural modifications in Ni-Fe/MgAl2O4 catalysts employed for ethanol steam reforming

The effect of the UGT1A128 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis

Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small Cell Lung Cancer

7163 Phase II study of eribulin (Halichondrin B analogue, E7389) in patients with advanced urothelial cancer (AUC) – California Cancer Consortium led NCI/CTEP-sponsored trial

Abstract IA20: Linking tumor genomics to patient outcomes through a large-scale patient-derived xenograft (PDX) platform

Suchergebnisse filtern